Pfizer Inc. $PFE Stock Holdings Lifted by Canada Post Corp Registered Pension Plan

Canada Post Corp Registered Pension Plan raised its position in shares of Pfizer Inc. (NYSE:PFE) by 13.8% in the fourth quarter, Holdings Channel reports. The firm owned 390,128 shares of the biopharmaceutical company’s stock after buying an additional 47,286 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Pfizer were worth $9,714,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in PFE. Franklin Resources Inc. lifted its stake in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after acquiring an additional 8,108,887 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the last quarter. Neuberger Berman Group LLC raised its holdings in shares of Pfizer by 203.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock valued at $229,346,000 after purchasing an additional 6,045,763 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Pfizer by 120.9% in the 3rd quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock valued at $230,986,000 after purchasing an additional 5,202,884 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on PFE. Royal Bank Of Canada reissued an “underperform” rating and set a $25.00 target price on shares of Pfizer in a research report on Monday, April 20th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Guggenheim raised their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.84.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Pfizer Price Performance

Shares of PFE stock opened at $25.31 on Friday. Pfizer Inc. has a 12 month low of $22.45 and a 12 month high of $28.75. The company has a market capitalization of $144.25 billion, a P/E ratio of 19.32 and a beta of 0.35. The stock has a 50 day moving average of $26.98 and a two-hundred day moving average of $26.19. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.